Labidi Moujahed, Baillot Richard, Dionne Brigitte, Lacasse Yves, Maltais François, Boulet Louis-Philippe
Centre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada.
Centre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada.
Chest. 2009 Dec;136(6):1604-1611. doi: 10.1378/chest.09-0689. Epub 2009 Jul 6.
Pleural effusion is a common complication of cardiac surgery, but its characteristics and predisposing factors should be documented further. Our objective was to determine the prevalence, characteristics, and determinants of clinically significant pleural effusions, defined as those requiring therapeutic pleural drainage according to clinical assessment.
The prevalence and characteristics of patients who had a pleural effusion within 30 days of undergoing coronary artery bypass graft, valve replacement, or both were analyzed retrospectively at our institution over a 2-year period.
Among the 2,892 patients included in the study (mean age, 66 years; men, 2,139), 192 patients (6.6%) had experienced a clinically significant pleural effusion in the 30 days postsurgery. These effusions occurred after a mean (+/- SD) duration of 6.6 +/- 5.9 days following interventions. Pleural fluid analysis was obtained in 114 patients (59.4%); all met the criteria for an exudate. Pleural fluid was hemorrhagic in 50% of cases. Age, body weight, baseline pulmonary function, and smoking status were similar between patients with and without effusion; however, the proportion of women; the number of patients with previous conditions of heart failure, atrial fibrillation, or peripheral vascular disease; and the number of patients receiving therapy with an anticoagulant or antiarrhythmic agent was higher in the pleural effusion group. Patients with pleural effusion had an increased prevalence of postoperative complications.
Pleural effusion is a common complication of heart surgery, is associated with other postoperative complications, and is more frequent in women and in patients with associated cardiac or vascular comorbidities and medications used to treat those conditions.
ClinicalTrials.gov Identifier: NCT00665015.
胸腔积液是心脏手术常见的并发症,但其特征和诱发因素仍需进一步记录。我们的目的是确定具有临床意义的胸腔积液的患病率、特征和决定因素,将其定义为根据临床评估需要进行治疗性胸腔引流的胸腔积液。
我们对本机构2年内接受冠状动脉搭桥术、瓣膜置换术或两者皆有的患者在术后30天内发生胸腔积液的患病率和特征进行了回顾性分析。
纳入研究的2892例患者(平均年龄66岁;男性2139例)中,192例(6.6%)在术后30天内出现了具有临床意义的胸腔积液。这些积液在干预后平均(±标准差)6.6±5.9天出现。114例患者(59.4%)进行了胸腔积液分析;所有结果均符合渗出液标准。50%的病例胸腔积液为血性。有胸腔积液和无胸腔积液的患者在年龄、体重、基线肺功能和吸烟状况方面相似;然而,胸腔积液组女性比例、既往有心力衰竭、心房颤动或外周血管疾病的患者数量以及接受抗凝剂或抗心律失常药物治疗的患者数量更高。有胸腔积液的患者术后并发症的患病率更高。
胸腔积液是心脏手术常见的并发症,与其他术后并发症相关,在女性以及伴有心脏或血管合并症和用于治疗这些疾病的药物的患者中更常见。
ClinicalTrials.gov标识符:NCT00665015。